HIV-associated facial lipoatrophy

被引:95
作者
James, J
Carruthers, A
Carruthers, J
机构
[1] Univ British Columbia, Div Dermatol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada
关键词
D O I
10.1046/j.1524-4725.2002.02099.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
BACKGROUND. HIV-infected individuals are living long, healthy lives. They are now concerned with less life-threatening problems, especially lipodystrophy. objective. To review the current state of our knowledge about lipodystrophy in HIV-infected individuals. METHODS. The literature was reviewed and analyzed for relevant information. In addition, our clinical experience of managing such individuals was utilized. RESULTS. Lipodystrophy and facial lipoatrophy and their relationship to HIV-infection are discussed. Their differences are noted. The spectrum of appearance in individuals with facial lipoatrophy is described and a severity scale suggested which should be of value in assessing the results of treatment. CONCLUSION. Lipodystrophy and lipoatrophy are intimately related to infection with HIV. In consequence, facial lipoatrophy is a major stigma for HIV-infected individuals and can have dramatic effects on their self-esteem and socialization. Effective treatment is essential.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 55 条
[1]
THE USE OF EXPANDED POLYTETRAFLUORETHYLENE AS A PERMANENT FILLER AND ENHANCER - AN EARLY REPORT OF EXPERIENCE [J].
ARTZ, JS ;
DINNER, MI .
ANNALS OF PLASTIC SURGERY, 1994, 32 (05) :457-462
[2]
BENDER BS, 1993, SURG CLIN N AM, V73, P373
[3]
Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors:: Association with the development of lipodystrophy [J].
Bonnet, E ;
Ruidavets, JB ;
Tuech, J ;
Ferrières, J ;
Collet, X ;
Fauvel, J ;
Massip, P ;
Perret, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :296-302
[4]
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[5]
Burres S, 2001, CLIN PLAST SURG, V28, P101
[6]
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[7]
HIV protease inhibitor-related lipodystrophy syndrome [J].
Carr, A .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S135-S142
[8]
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[9]
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[10]
Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430